Both Evelo Biosciences Inc. (NASDAQ:EVLO) and Adaptimmune Therapeutics plc (NASDAQ:ADAP) are Biotechnology companies, competing one another. We will contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adaptimmune Therapeutics plc 62.30M 7.67 86.60M -0.93 0.00 Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 represents Evelo Biosciences Inc. (NASDAQ:EVLO) and Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s return on assets, net margins and return on equity.
The Current Ratio and a Quick Ratio of Evelo Biosciences Inc. are 17.9 and 17.9. Competitively, Adaptimmune Therapeutics plc has 8.8 and 8.8 for Current and Quick Ratio. Evelo Biosciences Inc.’s better ability to pay short and long-term obligations than Adaptimmune Therapeutics plc.
Evelo Biosciences Inc. and Adaptimmune Therapeutics plc Recommendations and Ratings are available in the next table.
Competitively Adaptimmune Therapeutics plc has a consensus price target of $16, with potential upside of 250.11%.
Insider & Institutional Ownership
Institutional investors held 85% of Evelo Biosciences Inc. shares and 63% of Adaptimmune Therapeutics plc shares. About 2.69% of Evelo Biosciences Inc.’s share are held by insiders. Insiders Comparatively, held 0.23% of Adaptimmune Therapeutics plc shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Evelo Biosciences Inc. 5.85% 6.06% -19.48% -24.46% 0% -35.38% Adaptimmune Therapeutics plc -4.71% -11.73% -45.95% -52.58% -26.44% -12.13% For the past year Evelo Biosciences Inc. was more bearish than Adaptimmune Therapeutics plc.
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Click here to view original web page at Evelo Biosciences Inc. (EVLO)’s Financial Results Comparing With Adaptimmune Therapeutics plc (NASDAQ:ADAP)